Structural Biology of the Tumor Suppressor p53 and Cancer-Associated Mutants

Advances in Cancer Research

Volumn 97, Issue , 2007, Pages 1-23

  Joerger, Andreas C ^a   Fersht, Alan R ^a  

^a MRC CENTRE FOR PROTEIN ENGINEERING   (United Kingdom)

Author keywords

containing the four point mutations M133L; N239Y; N268D; p53 core domain; p53C; T p53C; V203A

Indexed keywords

4 (3 DIMETHYLAMINOPROPYLAMINO) 2 (4 METHOXYSTYRYL)QUINAZOLINE; DOUBLE STRANDED DNA; HISTONE ACETYLTRANSFERASE PCAF; MUTANT PROTEIN; PROTEIN MDM2; PROTEIN P53;

APOPTOSIS; BIOPHYSICS; BREAST CANCER; CELL CYCLE ARREST; CRYSTAL STRUCTURE; CRYSTALLOGRAPHY; DNA BINDING; DNA DAMAGE; GENE MUTATION; HUMAN; MOLECULAR WEIGHT; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN STABILITY; PROTEIN STRUCTURE; REVIEW; SENESCENCE; THERMODYNAMICS; WILD TYPE;

ANTINEOPLASTIC AGENTS; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; DNA, NEOPLASM; DRUG DELIVERY SYSTEMS; DRUG DESIGN; GENES, P53; HUMANS; MODELS, MOLECULAR; MUTATION; NEOPLASMS; PROTEIN CONFORMATION; PROTEIN DENATURATION; PROTEIN STRUCTURE, TERTIARY; STRUCTURE-ACTIVITY RELATIONSHIP; SUPPRESSION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34047174813     PISSN: 0065230X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-230X(06)97001-8     Document Type: Review

References (83)

1. Ang H.C., Joerger A.C., Mayer S., and Fersht A.R. Effects of common cancer mutations on stability and DNA binding of full-length p53 compared with isolated core domains. J. Biol. Chem. 281 (2006) 21934-21941
2. Balagurumoorthy P., Sakamoto H., Lewis M.S., Zambrano N., Clore G.M., Gronenborn A.M., Appella E., and Harrington R.E. Four p53 DNA-binding domain peptides bind natural p53-response elements and bend the DNA. Proc. Natl. Acad. Sci. USA 92 (1995) 8591-8595
3. Baroni T.E., Wang T., Qian H., Dearth L.R., Truong L.N., Zeng J., Denes A.E., Chen S.W., and Brachmann R.K. A global suppressor motif for p53 cancer mutants. Proc. Natl. Acad. Sci. USA 101 (2004) 4930-4935
4. Brachmann R.K., Yu K., Eby Y., Pavletich N.P., and Boeke J.D. Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations. EMBO J. 17 (1998) 1847-1859
5. Braithwaite A.W., Del Sal G., and Lu X. Some p53-binding proteins that can function as arbiters of life and death. Cell Death Differ. 13 (2006) 984-993
6. Bullock A.N., Henckel J., DeDecker B.S., Johnson C.M., Nikolova P.V., Proctor M.R., Lane D.P., and Fersht A.R. Thermodynamic stability of wild-type and mutant p53 core domain. Proc. Natl. Acad. Sci. USA 94 (1997) 14338-14342
7. Bullock A.N., Henckel J., and Fersht A.R. Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: Definition of mutant states for rescue in cancer therapy. Oncogene 19 (2000) 1245-1256
8. Bykov V.J., Selivanova G., and Wiman K.G. Small molecules that reactivate mutant p53. Eur. J. Cancer 39 (2003) 1828-1834
9. Canadillas J.M., Tidow H., Freund S.M., Rutherford T.J., Ang H.C., and Fersht A.R. Solution structure of p53 core domain: Structural basis for its instability. Proc. Natl. Acad. Sci. USA 103 (2006) 2109-2114
10. Chan W.M., Siu W.Y., Lau A., and Poon R.Y. How many mutant p53 molecules are needed to inactivate a tetramer?. Mol. Cell. Biol. 24 (2004) 3536-3551
11. Chen J.Y., Funk W.D., Wright W.E., Shay J.W., and Minna J.D. Heterogeneity of transcriptional activity of mutant p53 proteins and p53 DNA target sequences. Oncogene 8 (1993) 2159-2166
12. Cho Y., Gorina S., Jeffrey P.D., and Pavletich N.P. Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. Science 265 (1994) 346-355
13. Chumakov A.M., Miller C.W., Chen D.L., and Koeffler H.P. Analysis of p53 transactivation through high-affinity binding sites. Oncogene 8 (1993) 3005-3011
14. Clore G.M., Omichinski J.G., Sakaguchi K., Zambrano N., Sakamoto H., Appella E., and Gronenborn A.M. High-resolution structure of the oligomerization domain of p53 by multidimensional NMR. Science 265 (1994) 386-391
15. Clore G.M., Ernst J., Clubb R., Omichinski J.G., Kennedy W.M., Sakaguchi K., Appella E., and Gronenborn A.M. Refined solution structure of the oligomerization domain of the tumour suppressor p53. Nat. Struct. Biol. 2 (1995) 321-333
16. Courtois S., de Fromentel C.C., and Hainaut P. p53 protein variants: Structural and functional similarities with p63 and p73 isoforms. Oncogene 23 (2004) 631-638
17. Dawson R., Muller L., Dehner A., Klein C., Kessler H., and Buchner J. The N-terminal domain of p53 is natively unfolded. J. Mol. Biol. 332 (2003) 1131-1141
18. Derbyshire D.J., Basu B.P., Serpell L.C., Joo W.S., Date T., Iwabuchi K., and Doherty A.J. Crystal structure of human 53BP1 BRCT domains bound to p53 tumour suppressor. EMBO J. 21 (2002) 3863-3872
19. Di Como C.J., and Prives C. Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay. Oncogene 16 (1998) 2527-2539
20. DiTullio Jr. R.A., Mochan T.A., Venere M., Bartkova J., Sehested M., Bartek J., and Halazonetis T.D. 53BP1 functions in an ATM-dependent checkpoint pathway that is constitutively activated in human cancer. Nat. Cell Biol. 4 (2002) 998-1002
21. el-Deiry W.S., Kern S.E., Pietenpol J.A., Kinzler K.W., and Vogelstein B. Definition of a consensus binding site for p53. Nat. Genet. 1 (1992) 45-49
22. Foster B.A., Coffey H.A., Morin M.J., and Rastinejad F. Pharmacological rescue of mutant p53 conformation and function. Science 286 (1999) 2507-2510
23. Friedler A., Hansson L.O., Veprintsev D.B., Freund S.M., Rippin T.M., Nikolova P.V., Proctor M.R., Rüdiger S., and Fersht A.R. A peptide that binds and stabilizes p53 core domain: Chaperone strategy for rescue of oncogenic mutants. Proc. Natl. Acad. Sci. USA 99 (2002) 937-942
24. Friedler A., Veprintsev D.B., Hansson L.O., and Fersht A.R. Kinetic instability of p53 core domain mutants: Implications for rescue by small molecules. J. Biol. Chem. 278 (2003) 24108-24112
25. Friedler A., DeDecker B.S., Freund S.M., Blair C., Rüdiger S., and Fersht A.R. Structural distortion of p53 by the mutation R249S and its rescue by a designed peptide: Implications for "mutant conformation.". J. Mol. Biol. 336 (2004) 187-196
26. Friedler A., Veprintsev D.B., Freund S.M., von Glos K.I., and Fersht A.R. Modulation of binding of DNA to the C-terminal domain of p53 by acetylation. Structure 13 (2005) 629-636
27. Friedler A., Veprintsev D.B., Rutherford T., von Glos K.I., and Fersht A.R. Binding of Rad51 and other peptide sequences to a promiscuous, highly electrostatic binding site in p53. J. Biol. Chem. 280 (2005) 8051-8059
28. Gorina S., and Pavletich N.P. Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2. Science 274 (1996) 1001-1005
29. Grossman S.R. p300/CBP/p53 interaction and regulation of the p53 response. Eur. J. Biochem. 268 (2001) 2773-2778
30. Gu W., and Roeder R.G. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90 (1997) 595-606
31. Ho W.C., Fitzgerald M.X., and Marmorstein R. Structure of the p53 core domain dimer bound to DNA. J. Biol. Chem. 281 (2006) 20494-20502
32. Huyen Y., Jeffrey P.D., Derry W.B., Rothman J.H., Pavletich N.P., Stavridi E.S., and Halazonetis T.D. Structural differences in the DNA binding domains of human p53 and its C. elegans ortholog Cep-1. Structure 12 (2004) 1237-1243
33. Issaeva N., Friedler A., Bozko P., Wiman K.G., Fersht A.R., and Selivanova G. Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide. Proc. Natl. Acad. Sci. USA 100 (2003) 13303-13307
34. Jeffrey P.D., Gorina S., and Pavletich N.P. Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science 267 (1995) 1498-1502
35. Joerger A.C., Allen M.D., and Fersht A.R. Crystal structure of a superstable mutant of human p53 core domain. Insights into the mechanism of rescuing oncogenic mutations. J. Biol. Chem. 279 (2004) 1291-1296
36. Joerger A.C., Ang H.C., Veprintsev D.B., Blair C.M., and Fersht A.R. Crystal structures of p53 cancer mutants and mechanism of rescue by second-site suppressor mutations. J. Biol. Chem. 280 (2005) 16030-16037
37. Joerger A.C., Ang H.C., and Fersht A.R. Structural basis for understanding oncogenic p53 mutations and designing rescue drugs. Proc. Natl. Acad. Sci. USA 103 (2006) 15056-15061
38. Joo W.S., Jeffrey P.D., Cantor S.B., Finnin M.S., Livingston D.M., and Pavletich N.P. Structure of the 53BP1 BRCT region bound to p53 and its comparison to the Brca1 BRCT structure. Genes Dev. 16 (2002) 583-593
39. Kitayner M., Rozenberg H., Kessler N., Rabinovich D., Shaulov L., Haran T.E., and Shakked Z. Structural basis of DNA recognition by p53 tetramers. Mol. Cell 22 (2006) 741-753
40. Klein C., Planker E., Diercks T., Kessler H., Kunkele K.P., Lang K., Hansen S., and Schwaiger M. NMR spectroscopy reveals the solution dimerization interface of p53 core domains bound to their consensus DNA. J. Biol. Chem. 276 (2001) 49020-49027
41. Krajewski M., Ozdowy P., D'Silva L., Rothweiler U., and Holak T.A. NMR indicates that the small molecule RITA does not block p53-MDM2 binding in vitro. Nat. Med. 11 (2005) 1135-1136 author reply, 1136-1137
42. Kraulis P.J. MOLSCRIPT: A program to produce both detailed and schematic plots of protein structures. J. Appl. Crystallogr. 24 (1991) 946-950
43. Kussie P.H., Gorina S., Marechal V., Elenbaas B., Moreau J., Levine A.J., and Pavletich N.P. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274 (1996) 948-953
44. Lavin M.F., and Gueven N. The complexity of p53 stabilization and activation. Cell Death Differ. 13 (2006) 941-950
45. Lee H., Mok K.H., Muhandiram R., Park K.H., Suk J.E., Kim D.H., Chang J., Sung Y.C., Choi K.Y., and Han K.H. Local structural elements in the mostly unstructured transcriptional activation domain of human p53. J. Biol. Chem. 275 (2000) 29426-29432
46. Matsumura I., and Ellington A.D. In vitro evolution of thermostable p53 variants. Protein Sci. 8 (1999) 731-740
47. Menendez D., Inga A., and Resnick M.A. The biological impact of the human master regulator p53 can be altered by mutations that change the spectrum and expression of its target genes. Mol. Cell. Biol. 26 (2006) 2297-2308
48. Merritt E.A., and Bacon D.J. Raster3D: Photorealistic molecular graphics. Methods Enzymol. 277 (1997) 505-524
49. Michael D., and Oren M. The p53 and Mdm2 families in cancer. Curr. Opin. Genet. Dev. 12 (2002) 53-59
50. Michael D., and Oren M. The p53-Mdm2 module and the ubiquitin system. Semin. Cancer. Biol. 13 (2003) 49-58
51. Mittl P.R., Chene P., and Grutter M.G. Crystallization and structure solution of p53 (residues 326-356) by molecular replacement using an NMR model as template. Acta Crystallogr. D 54 (1998) 86-89
52. Momand J., Wu H.H., and Dasgupta G. MDM2-master regulator of the p53 tumor suppressor protein. Gene 242 (2000) 15-29
53. Müller-Tiemann B.F., Halazonetis T.D., and Elting J.J. Identification of an additional negative regulatory region for p53 sequence-specific DNA binding. Proc. Natl. Acad. Sci. USA 95 (1998) 6079-6084
54. Nikolova P.V., Henckel J., Lane D.P., and Fersht A.R. Semirational design of active tumor suppressor p53 DNA binding domain with enhanced stability. Proc. Natl. Acad. Sci. USA 95 (1998) 14675-14680
55. Nikolova P.V., Wong K.B., DeDecker B., Henckel J., and Fersht A.R. Mechanism of rescue of common p53 cancer mutations by second-site suppressor mutations. EMBO J. 19 (2000) 370-378
56. Olivier M., Eeles R., Hollstein M., Khan M.A., Harris C.C., and Hainaut P. The IARC TP53 database: New online mutation analysis and recommendations to users. Hum. Mutat. 19 (2002) 607-614
57. Olivier M., Langerod A., Carrieri P., Bergh J., Klaar S., Eyfjord J., Theillet C., Rodriguez C., Lidereau R., Bieche I., Varley J., Bignon Y., et al. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin. Cancer Res. 12 (2006) 1157-1167
58. Pan Y., Ma B., Levine A.J., and Nussinov R. Comparison of the human and worm p53 structures suggests a way for enhancing stability. Biochemistry 45 (2006) 3925-3933
59. Pietenpol J.A., Tokino T., Thiagalingam S., el-Deiry W.S., Kinzler K.W., and Vogelstein B. Sequence-specific transcriptional activation is essential for growth suppression by p53. Proc. Natl. Acad. Sci. USA 91 (1994) 1998-2002
60. Prives C., and Hall P.A. The p53 pathway. J. Pathol. 187 (1999) 112-126
61. Prives C., and Manley J.L. Why is p53 acetylated?. Cell 107 (2001) 815-818
62. Resnick M.A., and Inga A. Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity. Proc. Natl. Acad. Sci. USA 100 (2003) 9934-9939
63. Rippin T.M., Bykov V.J., Freund S.M., Selivanova G., Wiman K.G., and Fersht A.R. Characterization of the p53-rescue drug CP-31398 in vitro and in living cells. Oncogene 21 (2002) 2119-2129
64. Rippin T.M., Freund S.M., Veprintsev D.B., and Fersht A.R. Recognition of DNA by p53 core domain and location of intermolecular contacts of cooperative binding. J. Mol. Biol. 319 (2002) 351-358
65. Rustandi R.R., Baldisseri D.M., and Weber D.J. Structure of the negative regulatory domain of p53 bound to S100B(betabeta). Nat. Struct. Biol. 7 (2000) 570-574
66. Sakaguchi K., Sakamoto H., Xie D., Erickson J.W., Lewis M.S., Anderson C.W., and Appella E. Effect of phosphorylation on tetramerization of the tumor suppressor protein p53. J. Protein Chem. 16 (1997) 553-556
67. Shaulsky G., Goldfinger N., Ben-Zeev A., and Rotter V. Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis. Mol. Cell. Biol. 10 (1990) 6565-6577
68. Shiraishi K., Kato S., Han S.Y., Liu W., Otsuka K., Sakayori M., Ishida T., Takeda M., Kanamaru R., Ohuchi N., and Ishioka C. Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library. J. Biol. Chem. 279 (2004) 348-355
69. Stommel J.M., Marchenko N.D., Jimenez G.S., Moll U.M., Hope T.J., and Wahl G.M. A leucine-rich nuclear export signal in the p53 tetramerization domain: Regulation of subcellular localization and p53 activity by NES masking. EMBO J. 18 (1999) 1660-1672
70. Tanner S., and Barberis A. CP-31398, a putative p53-stabilizing molecule tested in mammalian cells and in yeast for its effects on p53 transcriptional activity. J. Negat. Results Biomed. 3 (2004) 5
71. Tidow H., Veprintsev D.B., Freund S.M.V., and Fersht A.R. Effects of oncogenic mutations and DNA response elements on the binding of p53 and p53-binding protein 2 (53BP2). J. Biol. Chem. 281 (2006) 32526-32533
72. Veprintsev D.B., Freund S.M., Andreeva A., Rutledge S.E., Tidow H., Canadillas J.M., Blair C.M., and Fersht A.R. Core domain interactions in full-length p53 in solution. Proc. Natl. Acad. Sci. USA 103 (2006) 2115-2119
73. Vogelstein B., Lane D., and Levine A.J. Surfing the p53 network. Nature 408 (2000) 307-310
74. Vousden K.H., and Lu X. Live or let die: The cell's response to p53. Nat. Rev. Cancer 2 (2002) 594-604
75. Walker K.K., and Levine A.J. Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc. Natl. Acad. Sci. USA 93 (1996) 15335-15340
76. Wang W., Takimoto R., Rastinejad F., and El-Deiry W.S. Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding. Mol. Cell. Biol. 23 (2003) 2171-2181
77. Weinberg R.L., Freund S.M., Veprintsev D.B., Bycroft M., and Fersht A.R. Regulation of DNA binding of p53 by its C-terminal domain. J. Mol. Biol. 342 (2004) 801-811
78. Weinberg R.L., Veprintsev D.B., and Fersht A.R. Cooperative binding of tetrameric p53 to DNA. J. Mol. Biol. 341 (2004) 1145-1159
79. Wieczorek A.M., Waterman J.L., Waterman M.J., and Halazonetis T.D. Structure-based rescue of common tumor-derived p53 mutants. Nat. Med. 2 (1996) 1143-1146
80. Wiman K.G. Strategies for therapeutic targeting of the p53 pathway in cancer. Cell Death Differ. 13 (2006) 921-926
81. Wong K.B., DeDecker B.S., Freund S.M., Proctor M.R., Bycroft M., and Fersht A.R. Hot-spot mutants of p53 core domain evince characteristic local structural changes. Proc. Natl. Acad. Sci. USA 96 (1999) 8438-8442
82. Zhan M., Yu D., Lang A., Li L., and Pollock R.E. Wild type p53 sensitizes soft tissue sarcoma cells to doxorubicin by down-regulating multidrug resistance-1 expression. Cancer 92 (2001) 1556-1566
83. Zhang W., Guo X.Y., Hu G.Y., Liu W.B., Shay J.W., and Deisseroth A.B. A temperature-sensitive mutant of human p53. EMBO J. 13 (1994) 2535-2544